Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed ... the company said it continued to make progress on building out its ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.